Prot #EFC15824: A Phase 3, randomized, double-blind, global, placebo-controlled study to assess the efficacy and safety of alemtuzumab in participants with primary progressive multiple sclerosis (RUBY)

Project: Research project

Project Details

StatusFinished
Effective start/end date4/2/19 → 4/2/20

Funding

  • Sanofi US Services Inc. (Prot #EFC15824)